APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants

The V179I substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is selected in humans or mouse models treated with certain nonnucleoside reverse transcriptase inhibitors (NNRTIs). While it is often observed together with other NNRTI resistance mutations, V179I does n...

Full description

Bibliographic Details
Main Authors: Richa Dwivedi, Youya Wang, Christopher Kline, Douglas K. Fischer, Zandrea Ambrose
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Virology
Subjects:
HIV
reverse transcriptase (RT)
drug resistance
non-nucleoside RT inhibitor (NNRTI)
APOBEC3
humanized mouse model
Online Access:https://www.frontiersin.org/articles/10.3389/fviro.2022.919825/full

Internet

https://www.frontiersin.org/articles/10.3389/fviro.2022.919825/full

Similar Items